Abstract Body

Background

Tuberculosis (TB) remains a global health challenge, with an estimated 10.8 million cases reported annually. Although the standard 6-month regimen-comprising isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE)-is effective in clinical trials, its long duration leads to poor adherence and adverse outcomes in practice. Positive culture at month 2 (PCM2) has traditionally served as a milestone endpoint, but its predictive value for novel regimens is limited. Alternative culture-based biomarkers, such as time to stable sputum culture conversion (TSCC) and longitudinal time to positivity (TTP), may correlate more strongly with clinical outcomes and serve as surrogate markers, though their role is not yet established. This study aims to identify a robust surrogate culture biomarker in phase 2 and 3 clinical trials.

Methods

Individual participant data from four phase 2 and 3 clinical trials (Study 31/A5349 [S31], RIFAQUIN, REMoxTB, and OFLOTUB), comprising 8 distinct treatment arms, were analyzed. Six culture readouts were evaluated: PCM2, TSCC, TTP at baseline, and TTP slopes over 0–2, 0–4, and 0–8 weeks. Associations with TB-related unfavorable outcomes were assessed using multivariate Cox proportional hazard models, stratified by treatment arm. 

Results

A total of 6,418 participant records were analyzed. Each biomarker was adjusted for severity of diseases, as defined by SPECTRA risk stratification algorithm. Both PCM2 and TSCC were associated with TB-related unfavorable outcomes across treatment arms, with the exceptions of the regimen consisting of 2 months of daily ethambutol, moxifloxacin, rifampicin, and pyrazinamide followed by 4 months of once-weekly moxifloxacin and rifapentine (2EMRZ/4P1M1) from RIFAQUIN trial (Figure 1). These findings suggest that both PCM2 and TSCC are promising prognostic biomarkers for phase 2 and 3 clinical trials. 

Conclusions

This study provides supportive evidence for the potential use of TSCC as a surrogate marker in phase 2 and 3 TB trials. While associations were generally consistent across treatment arms, observed exceptions highlight the need for further validation. Establishing TSCC as a reliable surrogate could facilitate earlier assessment of treatment efficacy, optimize trial design, and accelerate the development of novel TB regimens.

Table or Figure